Conference

ReNeuron Group plc
05 June 2006


        ReNeuron to participate in European Stem Cells & Regenerative 
                           Medicine Congress 2006


Guildford, UK, 5 June 2006: ReNeuron Group plc (LSE: RENE.L) today announces
that it will participate in the European Stem Cells & Regenerative Medicine
Congress 2006 at the Jumeirah Carlton Tower Hotel, London on June 5-7.


Michael Hunt, Chief Executive Officer of ReNeuron, will present an overview of
the Company's technology and ReN001 stroke programme, and participate in a panel
discussion concerning the commercialisation of stem cell technologies, scheduled
for 14:00 BST on 7 June.


More information about the conference may be found at www.lifescienceworld.com/
2006/stemcells.


Enquiries:


ReNeuron
Michael Hunt, Chief Executive Officer                 Tel: [phone]

Financial Dynamics
David Yates                                           Tel: [phone]
Sarah Macleod


Notes to Editors


About ReNeuron Group plc


ReNeuron is a leading, UK-based adult stem cell therapy business.  The Company
is applying its novel stem cell platform technologies in the development of
ground-breaking stem cell therapies to serve significant and unmet or poorly-met
clinical needs.


ReNeuron has used its c-mycERTAM technology to generate genetically stable
neural stem cell lines.  This technology platform has multi-national patent
protection and is fully regulated by means of a chemically-induced safety
switch.  Cell growth can therefore be completely arrested prior to in vivo
implantation.


The Company's lead stem cell therapy, ReN001 for chronic stroke disability, is
in late pre-clinical development.  Subject to successful completion of
pre-clinical testing, the Company plans to file for approval to commence initial
clinical trials in stroke later this year, with trials commencing as soon as
possible thereafter.


The Company has also generated pre-clinical efficacy data with its ReN005 stem
cell therapy for Huntington's disease, a rare, genetic and fatal
neurodegenerative disorder which affects around 1 in 10,000 people.  This
programme is in pre-clinical development.


In addition to its stroke and Huntington's disease programmes, ReNeuron is
developing stem cell therapies for Parkinson's disease, Type 1 diabetes and
diseases of the retina.


ReNeuron has also leveraged its stem cell technologies into non-therapeutic
areas - its ReNcell range of cell lines for use in drug discovery applications
in the pharmaceutical industry.


ReNeuron's shares are traded on the London AIM market under the symbol RENE.L,
and its warrants are traded under the symbol RENW.L.


Further information on ReNeuron and its products can be found at
www.reneuron.com.


This announcement contains forward-looking statements with respect to the
financial condition, results of operations and business achievements/performance
of ReNeuron and certain of the plans and objectives of management of ReNeuron
with respect thereto. These statements may generally, but not always, be
identified by the use of words such as 'should', 'expects', 'estimates',
'believes' or similar expressions. This announcement also contains
forward-looking statements attributed to certain third parties relating to their
estimates regarding the growth of markets and demand for products. By their
nature, forward-looking statements involve risk and uncertainty because they
reflect ReNeuron's current expectations and assumptions as to future events and
circumstances that may not prove accurate.  A number of factors could cause
ReNeuron's actual financial condition, results of operations and business
achievements/performance to differ materially from the estimates made or implied
in such forward-looking statements and, accordingly, reliance should not be
placed on such statements.


The terms 'ReNeuron' or 'the Company' refer to ReNeuron Group plc and its
subsidiary undertakings.


                      This information is provided by RNS
            The company news service from the London Stock Exchange